| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Destiny Pharma starts preparation for phase 3 C. difficile infection study
StockMarketWire.com
|
Biotechnology company Destiny Pharma said it had commenced the work required to prepare for the phase 3 clinical study, set to start in 2022, for a biotherapeutic to prevent C. difficile infection.
Destiny Pharma also said it had signed a new contract with a biotherapeutics manufacturing company to establish a new NTCD-M3 process for the production of the phase 3 clinical trial doses.
'Establishing the new manufacturer will deliver a more efficient process and a lower cost product and is an important investment in the overall NTCD-M3 project,' the company said.
At 8:30am: (LON:DEST) Destiny Pharma Plc share price was 0p at 68.5p
Story provided by StockMarketWire.com
|
|
|
|
|
|
